3-fluoro-4-[(6-methylpyridin-3-yl)oxy]aniline | 871020-15-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-fluoro-4-[(6-methylpyridin-3-yl)oxy]aniline
• 英文别名: 3-fluoro-4-(6-methylpyridin-3-yl)oxyaniline
• CAS: 871020-15-4
• 化学式: C₁₂H₁₁FN₂O
• 分子量: 218.231
• InChiKey: FEDWTPDNMADLBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N'-[4-cyano-3-(2-hydroxyethoxy)-1H-pyrazol-5-yl]-N,N-dimethylimidoformamide 、 3-fluoro-4-[(6-methylpyridin-3-yl)oxy]aniline 以to give the title compound as a white solid (800 mg, 50%)的产率得到2-{[4-({3-fluoro-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]oxy}ethanol
  参考文献：
  名称：

  Pyrazolopyrimidine Compounds as Antitumor Agents

  摘要：

  本发明涉及式(I)的化合物，其中取代基如文本中所定义，用于在温血动物如人体内产生抗增殖作用，该作用单独或部分地通过抑制erbB2受体酪氨酸激酶来产生。

  公开号：

  US20080108613A1

文献信息

• [EN] QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES<br/>[FR] DERIVES DE QUINAZOLINE UTILISES COMME TYROSINE KINASES DU RECEPTEUR ERBB
  申请人：ASTRAZENECA AB

  公开号：WO2005118572A1

  公开（公告）日：2005-12-15

  The invention concerns quinazoline derivatives of the formula (I), wherein each of R1, R2, R3, R4, R5, R6, R7, X1, Q1, m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.

  该发明涉及公式(I)的喹唑啉衍生物，其中R1、R2、R3、R4、R5、R6、R7、X1、Q1、m和n中的每个都具有描述中定义的任意含义；它们的制备方法，含有它们的药物组合物以及它们在制造用作抗增殖剂的药物中的用途，用于预防或治疗对erbB受体酪氨酸激酶抑制敏感的肿瘤。
• Quinazoline Derivatives as Erbb Receptor Tyrosine kinases
  申请人：Bradbury Hugh Robert

  公开号：US20070232607A1

  公开（公告）日：2007-10-04

  The invention concerns quinazoline derivatives of the formula (I), wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X 1 , Q 1 , m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.

  这项发明涉及公式（I）的喹唑啉衍生物，其中R1、R2、R3、R4、R5、R6、R7、X1、Q1、m和n中的每一个都具有描述中定义的任何含义；它们的制备过程，含有它们的制药组合物以及它们在制造用作抗增殖剂的药物的过程中的使用，用于预防或治疗对erbB受体酪氨酸激酶抑制敏感的肿瘤。
• Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
  申请人：AstraZeneca AB

  公开号：US07947676B2

  公开（公告）日：2011-05-24

  The invention concerns compounds of the formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.

  本发明涉及式(I)化合物，其中取代基如文本中所定义，用于在温血动物（例如人）中产生抗增殖效应，该效应单独或部分地通过抑制erbB2受体酪氨酸激酶来产生。
• Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors
  作者：Richard Ducray、Peter Ballard、Bernard C. Barlaam、Mark D. Hickinson、Jason G. Kettle、Donald J. Ogilvie、Catherine B. Trigwell

  DOI：10.1016/j.bmcl.2007.12.035

  日期：2008.2

  Novel 4-anilino-1H-pyrazolo[3,4-d]pyrimidines have been synthesized and evaluated in vitro for erbB2 and EGFR kinase inhibition. A representative compound displaying oral bioavailability in rat and dog illustrates the potential of this series to provide orally active erbB2 inhibitors. (C) 2007 Elsevier Ltd. All rights reserved.
• QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES
  申请人：AstraZeneca AB

  公开号：EP1756088A1

  公开（公告）日：2007-02-28